Last reviewed · How we verify
Dose dense AC followed by T + trastuzumab
This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling.
This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling. Used for HER2-positive early-stage breast cancer (adjuvant or neoadjuvant therapy).
At a glance
| Generic name | Dose dense AC followed by T + trastuzumab |
|---|---|
| Sponsor | Agendia |
| Drug class | Chemotherapy regimen with monoclonal antibody |
| Target | HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Dose-dense AC (doxorubicin/cyclophosphamide) delivers chemotherapy at higher doses over shorter intervals to maximize cancer cell kill. Paclitaxel (T) is a taxane that stabilizes microtubules and prevents cell division. Trastuzumab is a monoclonal antibody targeting HER2 receptor on cancer cells, blocking growth signaling and recruiting immune-mediated cell death. This combination is used as adjuvant or neoadjuvant therapy in HER2-positive breast cancer.
Approved indications
- HER2-positive early-stage breast cancer (adjuvant or neoadjuvant therapy)
Common side effects
- Cardiotoxicity/congestive heart failure
- Neutropenia
- Anemia
- Nausea/vomiting
- Alopecia
- Peripheral neuropathy
- Fatigue
- Infusion reactions
Key clinical trials
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (PHASE4)
- Fasting on Newly Diagnosed Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose dense AC followed by T + trastuzumab CI brief — competitive landscape report
- Dose dense AC followed by T + trastuzumab updates RSS · CI watch RSS
- Agendia portfolio CI